Ata Bethesda Cytology Management

---
name: ata-bethesda-cytology-management
description: Guides next-step management after a thyroid FNA result using the Bethesda System for Reporting Thyroid Cytopathology (categories I–VI), integrating clinical risk, sonographic pattern, and molecular testing options. Use when a clinician asks "what do I do with a Bethesda III result", "Bethesda IV FNA what next", "should I repeat FNA or do molecular testing", "FLUS result management", "Bethesda II follow-up interval", or any question about acting on a thyroid FNA cytology report. Source: 2015 ATA Guidelines, Haugen et al., Thyroid 2016;26(1).
---

# ATA Bethesda Cytology Management Tool
**Source:** 2015 ATA Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Haugen et al. Thyroid 2016;26(1). DOI: 10.1089/thy.2015.0020

---

## STEP 1 — Identify the Bethesda Category

| Bethesda Category | Cytologic Finding | Malignancy Risk* |
|---|---|---|
| **I** | Nondiagnostic / Unsatisfactory | 1–4% |
| **II** | Benign | 0–3% |
| **III** | Atypia of Undetermined Significance / Follicular Lesion of Undetermined Significance (AUS/FLUS) | ~5–15% |
| **IV** | Follicular Neoplasm / Suspicious for Follicular Neoplasm (FN/SFN) | 15–30% |
| **V** | Suspicious for Malignancy | 60–75% |
| **VI** | Malignant | 97–99% |

> *Malignancy risk based on surgical excision data from ATA Guidelines Table 6.

---

## STEP 2 — Apply the Management Algorithm by Category

### Bethesda I — Nondiagnostic / Unsatisfactory
- **Action:** Repeat FNA under ultrasound guidance
- Repeat after a minimum interval (allow any hematoma to resolve, typically 4–6 weeks)
- If repeat FNA is again nondiagnostic → consider surgical excision or close follow-up if the nodule is sonographically benign (very low suspicion)
- Cystic nodules with persistent nondiagnostic results + high-risk clinical features → consider surgery

---

### Bethesda II — Benign
- **Action:** No immediate surgery
- Follow-up by sonographic pattern (see intervals below)
- **Exceptions that warrant surgery/FNA despite benign cytology:**
  - High-risk clinical features (radiation history, family history DTC, vocal cord palsy, progressive growth)
  - Symptomatic nodule (compression, dysphagia)
  - Focal 18FDG-PET avidity in the same nodule

**Follow-up ultrasound intervals after benign FNA:**

| Sonographic Pattern | Follow-up US |
|---|---|
| High suspicion | 12 months |
| Low–intermediate suspicion | 12–24 months |
| Very low suspicion | 24+ months; consider no further follow-up if stable |
| Spongiform / predominantly cystic | No follow-up required |

> Two benign FNA results on the same nodule → US surveillance for malignancy no longer indicated (can discontinue FNA monitoring)

---

### Bethesda III — AUS / FLUS
- **Action:** Clinical and sonographic risk stratification guides next step

**Decision tree:**

1. **Repeat FNA** (preferred initial approach)
   - Repeat after 3 months (allow inflammation to resolve)
   - Use US guidance; consider different sampling technique
   - ~50–75% of repeats yield a definitive category

2. **Molecular testing** (if repeat FNA not desired or if repeated AUS/FLUS)
   - Mutational panel (BRAF, RAS, RET/PTC, PAX8/PPARγ) or gene expression classifier
   - Positive/high-risk molecular profile → proceed as Bethesda V
   - Negative/low-risk → surveillance may be appropriate

3. **Diagnostic surgery** (lobectomy preferred)
   - Indicated if: high-risk sonographic features, high-risk clinical history, repeat FNA again AUS/FLUS, or patient preference

---

### Bethesda IV — Follicular Neoplasm / Suspicious for FN
- **Action:** Diagnostic surgical excision (lobectomy)
- Rationale: Cannot distinguish follicular adenoma from follicular carcinoma on cytology alone (vascular/capsular invasion needed on histology)
- **Molecular testing option:**
  - If negative → observation may be considered (discuss with patient)
  - If positive → proceed to surgery as planned
- Hürthle cell variant: lobectomy is standard; Hürthle cell carcinoma has distinct biology

---

### Bethesda V — Suspicious for Malignancy
- **Action:** Surgery — manage similarly to malignant cytology
- Near-total/total thyroidectomy if:
  - Nodule >4 cm
  - Bilateral nodular disease
  - High-risk clinical features
  - Patient preference
- Lobectomy may be sufficient if:
  - Nodule ≤4 cm
  - No clinical high-risk features
  - Absence of bilateral disease or lymphadenopathy

---

### Bethesda VI — Malignant
- **Action:** Surgery generally recommended
- **Approach depends on:**
  - Tumor size and extent
  - Presence of lymphadenopathy
  - Comorbidities and patient preference

| Finding | Preferred Surgical Approach |
|---|---|
| PTC ≥4 cm or gross ETE or LN involvement | Near-total / total thyroidectomy |
| Low-risk PTC 1–4 cm, no ETE, no LN | Lobectomy or total thyroidectomy (discuss) |
| PTC <1 cm (PTMC), no high-risk features | Active surveillance or lobectomy acceptable |
| Hurthle cell / FTC with aggressive features | Total thyroidectomy |

> PTMC <1 cm without high-risk features: active surveillance without immediate surgery is an acceptable alternative in selected patients

---

## STEP 3 — Preoperative Assessment Before Surgery (Bethesda IV–VI)

- **Neck ultrasound:** Evaluate cervical lymph nodes (central and lateral compartments) preoperatively
  - FNA any suspicious node (with Tg washout if needed)
- **Vocal cord assessment:** If hoarseness, voice change, or prior neck surgery → laryngoscopy
- **Do NOT routinely perform:** CT neck, PET scan, or bone scan — not indicated for standard low-risk workup

---

## CLINICAL GUARDRAILS

- **Bethesda II ≠ dismiss** — still requires US follow-up; two benign results on the same nodule over time can justify discontinuing surveillance
- **AUS/FLUS is not a diagnosis** — it is a category mandating further characterisation, not a final answer
- **Molecular testing augments but does not replace** surgical judgment for Bethesda III/IV — a negative panel lowers but does not eliminate risk
- **Lobectomy is not inferior** to total thyroidectomy for well-selected low-risk DTC — do not reflexively escalate to total thyroidectomy
- **Active surveillance for PTMC** is evidence-based; counsel patient on the option before recommending immediate surgery
- **High-risk clinical context overrides cytology** — a "benign" FNA in a patient with rapid growth, fixation, or lymphadenopathy should trigger surgical referral regardless of Bethesda category